Lenalidomid Stada (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4^CRBN E3 ubiquitin ligase complex. This binding changes the complex’s substrate preference, leading to the ubiquitination and subsequent proteasomal degradation of transcription factors Ikaros and Aiolos. The loss of these proteins produces anti‑angiogenic, anti‑proliferative, and immunomodulatory effects that suppress malignant plasma cells and modify the tumor microenvironment.

The dose of Lenalidomid Stada is individualized and set by the prescribing physician based on the specific indication, disease stage, patient’s renal function, prior therapies, and overall health status. Clinicians follow approved labeling and clinical guidelines to select the appropriate starting dose and any necessary adjustments.

Lenalidomid Stada is classified as pregnancy category X, meaning it is contraindicated in pregnancy because it can cause severe fetal harm, including birth defects. Women of child‑bearing potential must use effective contraception during treatment and for a defined period after the last dose. Breastfeeding is not recommended, as the drug may be excreted in milk.

To request Lenalidomid Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Lenalidomid Stada belongs to the same class of immunomodulatory drugs (IMiDs) as thalidomide and pomalidomide. Compared with thalidomide, lenalidomide generally offers greater potency with a more favorable peripheral neuropathy profile, while still sharing risks such as thrombosis and embryofetal toxicity. Pomalidomide is often reserved for patients who have progressed after lenalidomide therapy, reflecting a stepwise treatment approach within the class.

Lenalidomid Stada should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and avoid exposure to extreme heat. Do not refrigerate or freeze the tablets, as this could affect their stability.

Lenalidomid Stada is taken orally, usually as whole tablets swallowed with water. It can be taken with or without food, but patients should follow the prescribing physician’s instructions regarding timing relative to meals. The medication should not be crushed, chewed, or split unless specifically directed by a healthcare professional.

The most serious risks include venous thromboembolism (blood clots), severe neutropenia that can lead to life‑threatening infections, and embryo‑fetal toxicity that can cause major birth defects. Patients should be monitored closely for signs of clotting, infection, and any unexpected bleeding, and strict contraception must be used throughout treatment.

Lenalidomid Stada should not be used by pregnant women or women who could become pregnant without effective contraception. It is also contraindicated in patients with known hypersensitivity to lenalidomide or any component of the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled infections, or a history of thromboembolic events, and the prescriber should evaluate suitability before initiating therapy.